The recently released American College of Cardiology
|
|
- Toby Todd
- 6 years ago
- Views:
Transcription
1 Data Report Atherosclerotic Cardiovascular Disease Prevention A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, MD; Colby R. Ayers, MS; Jarett D. Berry, MD, MS; James A. de Lemos, MD; Amit Khera, MD, MSc Downloaded from by guest on May 3, 2018 The recently released American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines on the Treatment of Blood Cholesterol propose significant changes to current practice patterns. 1 The adoption of these new guidelines in place of the National Cholesterol Education Program/Third Adult Treatment panel (ATPIII) 2 recommendations has recently been estimated to result in an 11% increase in statin eligibility, representing 12.8 million Americans. 3 Although the magnitude of change in statin eligibility has been a topic of focus, the impact of the new guidelines on atherosclerotic cardiovascular disease (ASCVD) event rates and efficiency of additional statin use cannot be determined from the studies published to date. Knowledge of ASCVD event rates among reclassified individuals is essential to fully understand the implications of adopting the ACC/AHA guidelines. We sought to assess the implications of applying this new paradigm in place of the ATPIII recommendations on ASCVD event reduction and efficiency of statin utilization. Methods and Results The Dallas Heart Study is a multiethnic cohort of Dallas County residents, age 30 to 65 years, examined between 2000 and 2002 and actively followed for cardiovascular outcomes. 4 All participants provided informed consent, and the study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Sampling weights were applied to generate unbiased estimates of population frequencies in Dallas County. 4 The primary outcome of ASCVD was defined as coronary heart disease (CHD) death, myocardial infarction, and fatal and nonfatal stroke. 1 Secondary analysis was performed for CHD events (ie, CHD death and myocardial infarction). 2 Participants were classified as statin eligible or ineligible using (1) ATPIII recommendations including the Framingham Risk Score and low-density lipoprotein cholesterol levels and (2) ACC/AHA algorithm including the Pooled Cohort Equations (Table I in the Data Supplement). 1,2 Similar to prior studies, individuals on statins at baseline were considered eligible by both guidelines. 3 Reclassification of statin eligibility from ATPIII to the AHA/ ACC guidelines was determined, and ASCVD event rates were assessed among newly statin-eligible individuals. Net reclassification improvement was calculated as previously described. 5 Using the same framework applied in the ACC/ AHA guidelines, the number of prevented ASCVD events was estimated based on the number of events that occurred among statin-eligible individuals and assuming a relative risk reduction of 30% to 35% for moderate-intensity statin therapy and 45% for high-intensity statin therapy. 1 The number of statin-related excess cases of diabetes mellitus was estimated assuming 0.1 and 0.3 extra cases per 100 person-years for moderate- and high-intensity statin therapy, respectively. 1 Analyses were performed comparing the ACC/AHA guidelines with both the standard and optional low-density lipoprotein cholesterol goals from ATPIII. 2 A total of 2848 participants were assessed for statin eligibility according to both guidelines. Over a mean follow-up of 9.1±1.3 years, 129 ASCVD events including 70 CHD events occurred. After the application of sample weights, the median age of the population was 43 years, 49.9% were women, 19.0% were black, 7.9% had diabetes mellitus, and 3.4% had prior ASCVD (Table II in the Data Supplement). Overall, 17.2% of individuals were classified as statin eligible by ATPIII and 22.0% by the ACC/AHA guidelines (net increase 4.8%, relative increase 27.9%). The ASCVD event rate among newly statin-eligible individuals was 15.8% with an estimated one ASCVD event prevented for each additional 14 patients treated with high-dose statins and 21 treated with moderate-dose statins (Table). The net increase in statin eligibility was 37.1% among participants with ASCVD events and 3.9% among participants without ASCVD events, resulting in a net reclassification improvement of (P<0.001; Table III in the Data Supplement). Excluding individuals on statins at baseline resulted in a net 5.2% increase in statin eligibility with a 15.8% ASCVD event rate among the newly statin eligible and a similar number needed to treat. Results were also similar when the analysis was restricted to individuals 40 years old (Table; Table III in the Data Supplement). Received May 17, 2014; accepted June 25, From the Division of Cardiology (A.R.M.P., J.D.B., J.A.d.L., A.K.) and Department of Clinical Sciences (C.R.A., J.D.B.) at the University of Texas Southwestern Medical Center, Dallas. The Data Supplement is available at Correspondence to Amit Khera, MD, MSc, Division of Cardiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX amit.khera@utsouthwestern.edu (Circ Cardiovasc Qual Outcomes. 2014;7: ) 2014 American Heart Association, Inc. Circ Cardiovasc Qual Outcomes is available at DOI: /CIRCOUTCOMES
2 Paixao et al Comparison Between Cholesterol Guidelines 779 Downloaded from by guest on May 3, 2018 Table. Additional Statin Eligibility and ASCVD Event Rates Among Newly Statin Eligible Individuals Outcome Additional Statin Eligibility* Event Rate Among Newly Statin Eligible NNT Among Newly Statin Eligible Primary analysis ASCVD 4.8% 15.8% CHD 4.8% 11.7% ATPIII statin eligibility determined by optional cholesterol goals ASCVD 2.8% 15.7% CHD 2.8% 12.4% Restricting to individuals aged 40 years ASCVD 9.0% 15.8% CHD 9.0% 11.6% ASCVD indicates atherosclerotic cardiovascular disease; ATPIII, Third Adult Treatment panel; CHD, coronary heart disease; and NNT, number needed to treat. *Additional statin eligibility is the net product of those newly statin eligible and those no longer statin eligible under the new guidelines. Number needed to treat with moderate to high potency statin to prevent one atherosclerotic cardiovascular event assuming a 30% to 45% relative risk reduction. Applying the ACC/AHA guidelines in place of ATPIII would result in an additional 3.6 to 4.9 prevented ASCVD events for every 1000 individuals screened and accordingly treated with moderate- or high-dose statins, respectively, with 0.5 to 1.5 excess cases of diabetes mellitus (Figure I in the Data Supplement). When applied to the source population of Dallas County residents aged 30 to 65 (n= ), an additional 4479 to 4771 ASCVD events would be prevented. When the ACC/AHA guidelines were compared with the optional ATPIII low-density lipoprotein cholesterol goals, 2 even though a net reduction of 2.8% in statin eligibility was observed, newly statin-eligible individuals had an ASCVD event rate and number need to treat which were comparable to the primary analysis (Table) and a net reclassification improvement of (P<0.001; Table III in the Data Supplement). Restricting the outcome to CHD events yielded similar results (Table; Table III in the Data Supplement). Assuming a more conservative 25% ASCVD relative risk reduction for statin therapy, 6 the number needed to treat to prevent one event among newly statin-eligible individuals would be 25 and 2.7. ASCVD events would be prevented for every 1000 individuals screened and accordingly treated. Comment The release of the ACC/AHA guidelines was followed by a heated debate that was often centered on the expansion of statin eligibility. Our findings are consistent with a recent report from the National Health and Nutrition Examination Surveys and suggest that, among individuals <60 to 65 years, adopting the ACC/AHA guidelines would result in a modest absolute increase in statin eligibility. 3 Beyond reporting on additional statin use, we apply actual event rates to show that in this age group, additional statin use with adoption of the new guidelines seems reasonably efficient and effective. Newly statin-eligible individuals had high ASCVD event rates (15.8%), resulting in an efficient number needed to treat (14 21) to prevent one ASCVD event. Over one third of individuals with ASCVD events were newly classified as statin eligible, and there was an acceptable balance between prevented ASCVD events and new-onset diabetes mellitus. The implications for practitioners who have adopted the ATPIII optional low-density lipoprotein cholesterol goals would be more modest as switching to the ACC/AHA recommendations would actually decrease statin eligibility by 2.8% among individuals in this age range. The new guidelines, however, resulted in a more efficient use of statins with a 15.7% event rate among the newly statin eligible, translating into a persistent but lesser reduction in ASCVD events ( per 1000 screened). Our results from a contemporary, multiethnic, younger population suggest that the application of the ACC/AHA guidelines will have a favorable effect on ASCVD prevention with reasonable efficiency of statin use when compared with the prior ATPIII recommendations. The net effect of the new recommendations should also be assessed in older populations and in those with different ethnic composition. Sources of Funding The Dallas Heart Study was funded by the Donald W. Reynolds Foundation (Las Vegas, NE) and partially supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (Bethesda, MD) under award number UL1TR Disclosures Dr de Lemos has received honoraria and consulting fees from Astra Zeneca and consulting fees from Sanofi/Regeneron and Amgen. Dr Berry is a member of the Speakers Bureau for Merk & Co. The other authors report no conflicts. References 1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1 S Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44: Pencina MJ, Navar-Boggan AM, D Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370: Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH; Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93: Pencina MJ, D Agostino RB Sr, D Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27: Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD Key Words: cardiovascular diseases cholesterol
3 Atherosclerotic Cardiovascular Disease Prevention: A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, Colby R. Ayers, Jarett D. Berry, James A. de Lemos and Amit Khera Downloaded from by guest on May 3, 2018 Circ Cardiovasc Qual Outcomes. 2014;7: ; originally published online August 5, 2014; doi: /CIRCOUTCOMES Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX Copyright 2014 American Heart Association, Inc. All rights reserved. Print ISSN: Online ISSN: The online version of this article, along with updated information and services, is located on the World Wide Web at: Data Supplement (unedited) at: Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
4 Supplemental Material 1
5 Supplemental Table 1: ATPIII and ACC/AHA Guidelines Statin Eligibility Criteria ATPIII statin eligibility 1 Risk Category High risk (Clinical CVD*, diabetes or 2 risk Consider drug therapy LDL-C 2.6mmol/L (100mg/dL) Optional LDL-C 1.8mmol/L (70mg/dL) factors and FRS >20%) Moderately high risk ( 2 risk factors and FRS 10%-20%) Moderate risk LDL-C 3.4mmol/L (130mg/dL) Optional LDL-C 2.6mmol/L (100mg/dL) LDL-C 4.1mmol/L (160 mg/dl) ( 2 risk factors and FRS <10%) Low risk (0-1 risk factor ) LDL-C 4.9mmol/L (190 mg/dl) Optional LDL-C 4.1mmol/L (160mg/dL) 2013 ACC/AHA statin eligibility 2 Statin eligible groups Clinical CVD* LDL-C 4.9mmol/L (190 mg/dl) Diabetes and age 40 years PCE risk 7.5% and age 40 years and LDL-C 1.8mmol/L (70mg/dL) ATPIII = Third Adult Treatment panel, ACC = American College of Cardiology, AHA = American Heart Association, CVD = cardiovascular disease, FRS = Framingham Risk Score, LDL-C = low density lipoprotein cholesterol, PCE = Pooled Cohort Equations. 2
6 * Cardiovascular disease was defined as prior history of myocardial infarction, coronary revascularization or stroke. Risk factors include cigarette smoking, hypertension (blood pressure 140/90 mmhg or on antihypertensive medication), high density lipoprotein cholesterol <1.0mmol/L (40mg/dL), family history of premature coronary disease, and age (men 45 years; women 55 years). 3
7 Supplemental Table 2: Sample Weight-Adjusted Baseline Characteristics Characteristics Study population N 2848 Age* 43 [36, 52] Women 49.9% Race Black 19.0% White 54.9% Hispanic 23.2% Other 2.9% Smokers 24.1% Hypertension 26.3% TC (mg/dl) * 182 [159, 208] LDL-C (mg/dl) * 108 [86, 131] HDL-C (mg/dl) * 46 [38, 56] Triglycerides (mg/dl) * 105 [72, 159] Statins 6.2% Hypertension 18.3% medications 4
8 Diabetes 7.9% CVD 3.4% FRS * 1% [0,4] PCE * 1.7% [0.6, 4.4] TC = total cholesterol, LDL-C = low density lipoprotein, HDL-C = high density lipoprotein, CVD = Cardiovascular disease, FRS = Framingham risk score, PCE = Pooled Cohort Equations. Cardiovascular disease was defined as prior history of myocardial infarction, coronary revascularization or stroke. Framingham risk score and Pooled Cohort Equations are reported as 10 year risk estimates. *median [interquartile range] 5
9 Supplemental Table 3: Net Reclassification of Statin Eligibility among Individuals with and without ASCVD Events Outcome Additional statin Additional statin NRI p-value eligibility among events eligibility among nonevents Primary analysis ASCVD 37.1% 3.9% <0.01 CHD 40.4% 4.1% <0.01 ATPIII statin eligibility determined by optional cholesterol goals ASCVD 16.5% -3.4% <0.01 CHD 19.1% -3.2% <0.01 Restricting to individuals 40 years of age ASCVD 37.8% 7.6% <0.01 CHD 41.3% 8.0% <0.01 ASCVD = atherosclerotic cardiovascular disease, NRI = net reclassification improvement, CHD = coronary heart disease, ATPIII = Third Adult Treatment panel. 6
10 Supplemental Figure Implications of Applying the ACC/AHA Guidelines in Place of the ATPIII Recommendations per 1000 Individuals Screened AHA = American Heart Association, ACC = American College of Cardiology, ATPIII = Third Adult Treatment panel, ASCVD = atherosclerotic cardiovascular disease, LDL-C = low density lipoprotein cholesterol 7
11 References 1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Journal of the American College of Cardiology. 2004;44: Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr., Watson K, Wilson PW ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;129:S1 S45 8
Application of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationThe use of statins for primary prevention and evidencebased
Impact of Statin Guidelines on Statin Utilization and Costs in an Employer-Based Primary Care Clinic Holly E. Gurgle, PharmD, BCACP, CDE; Marisa B. Schauerhamer, PharmD; Simón A. Rodriguez, PharmD; and
More informationTHE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL
THE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL Anne Carol Goldberg, MD, FACP, FAHA, FNLA Associate Professor of Medicine Washington University School of Medicine National Lipid Association
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationAlthough the 2013 American College of Cardiology/
Implications of the US Cholesterol Guidelines on Eligibility for Statin Therapy in the Community: Comparison of Observed and Predicted Risks in the Framingham Heart Study Offspring Cohort Charlotte Andersson,
More informationSupplementary Online Content
Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices
More informationDefining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil
Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationCommon Cardiovascular Risk Calculators
PL Detail-Document #300102 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Common Cardiovascular
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationValidation of the pooled cohort risk score in an Asian population a retrospective cohort study
Chia et al. BMC Cardiovascular Disorders 2014, 14:163 RESEARCH ARTICLE Open Access Validation of the pooled cohort risk score in an Asian population a retrospective cohort study Yook Chin Chia 1,2*, Hooi
More informationPrimary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines
18 MEDICINSKI GLASNIK / str. 18-23 Vojislav Giga 1,2, Marija Petrović 1 Primary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines Abstract: European Society
More informationORIGINAL INVESTIGATION. Application of the Screening for Heart Attack Prevention and Education Task Force Recommendations to an Urban Population
ORIGINAL INVESTIGATION Application of the Screening for Heart Attack Prevention and Education Task Force Recommendations to an Urban Population Observations From the Dallas Heart Study Raphael See, MD;
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationAnalyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne
Abstract Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins Peter Thorne A sample of adults participating in the first 7 months of visit 5 of the Atherosclerosis
More informationUnderstanding US Lipid Guidelines-2013:
Presentation to NLA Symposium: May 3 2014 Understanding US Lipid Guidelines-2013: Neil J. Stone MD, MACP, FACC Bonow Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Il
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationDoes use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting
Chia et al. BMC Family Practice 2014, 15:172 RESEARCH ARTICLE Open Access Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting Yook
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationACC-AHA Prevention Guidelines: Evidence Continues to Lead the Way
IAS- Amsterdam -2015 ACC-AHA Prevention Guidelines: Evidence Continues to Lead the Way Neil J. Stone MD, MACP, FACC Bonow Professor of Medicine Feinberg School of Medicine Northwestern University Chicago,
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 10, 2014 ª 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 1, 214 ª 214 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 735-197/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jacc.214.6.1186
More informationNew Measure Recommended for Endorsement by PQA
New Measure Recommended for Endorsement by PQA Measure: Statin Use in Persons with Diabetes Description: The percentage of patients ages 40 75 years who were dispensed a medication for diabetes that receive
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationLDL-C treatment goals were introduced in the first National
Point/Counterpoint Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines Jennifer G. Robinson, Kausik Ray Abstract On the basis of accumulating evidence,
More informationStatinsshould be in the water supply. Lipid Drug Therapy: Use in Special Populations. Objectives. TSHP 2014 Annual Seminar 1
Lipid Drug Therapy: Use in Special Populations Mark C. Granberry, Pharm.D. Professor Texas A&M Rangel College of Pharmacy Objectives Discuss background for recommendations from the recent AHA/ACC Lipid
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationClinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk
1/5 MENU ORIGINAL RESEARCH 3 JULY 2018 Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk Article, Author, and Disclosure Information PREV
More informationApplicability and Cost Implications for PCKS9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights from the Department of Veterans Affairs
Applicability and Cost Implications for PCKS9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights from the Department of Veterans Affairs Running Title: Virani et al.; Applicability and Cost Implications
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationThe Art of Cardiovascular Risk Assessment
The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention
More informationComparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, : Review
European Journal of Environment and Public Health, 2017, 1(1), 04 ISSN: 2468-1997 Comparison of Abnormal Cholesterol in Children, Adolescent & Adults in the United States, 2011-2014: Review Rasaki Aranmolate
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationUse of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Accepted Manuscript Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA, Lynne T. Braun,
More informationTherapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines
Therapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines Paul Muntner, PhD a,b,, Dongfeng Gu, MD c, Robert F. Reynolds,
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More informationManageMent Review. Boback Ziaeian, MD, 1,2 John Dinkler, MD, MPH, 1,2 Karol Watson, MD, PhD 1,3 1
ManageMent Review Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationClinical Policy Title: Statin use in adults and children
Clinical Policy Title: Statin use in adults and children Clinical Policy Number: 04.02.09 Effective Date: May 1, 2016 Initial Review Date: February 17, 2016 Most Recent Review Date: September 21, 2017
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationCardio IQ. Managing Residual Risk with Advanced Cardiovascular Insights. Plaque Formation. Outward remodeling of arterial wall. Macrophages ingest
Cardio IQ Managing Residual Risk with Advanced Cardiovascular Insights Plaque Formation Plaque Progression Plaque Rupture Outward remodeling of arterial wall Normal Accumulation of modified LDL particles
More informationCardiovascular Risk Assessment: A Systematic Review of Guidelines.
Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Khanji, MY; Bicalho, VVS; van Waardhuizen, CN; Ferket, BS; Petersen, SE; Hunink, MGM 2016 American College of Physicians This is a pre-copyedited,
More information2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationClinical Investigations
Clinical Investigations Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Address for correspondence: Marcio Sommer Bittencourt, MD University
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationFamily history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study
1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands 2 Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands 3 Department of Public Health and
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationClinical Policy: Alirocumab (Praluent) Reference Number: CP.CPA.268 Effective Date: Last Review Date: 11.17
Clinical Policy: (Praluent) Reference Number: CP.CPA.268 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationSpeaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014
Speaker Disclosure Erica Pearce, Pharm.D. declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants,
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationStatin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines
Drugs Aging (2015) 32:87 93 DOI 10.1007/s40266-014-0238-5 CURRENT OPINION Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Yitzchak Weinberger Benjamin H. Han Published
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationSupplementary Online Content
Supplementary Online Content Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationCardiovascular Risk in Patients with Diabetes
PL Detail-Document #270516 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2011 Cardiovascular Risk
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationScreening for Cardiovascular Risk in Asymptomatic Patients
Journal of the American College of Cardiology Vol. 55, No. 12, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.066
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationNCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,
More informationLearning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III
Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:
More informationStatins and New Onset Diabetes Mellitus NPO
Learning Objectives 1) Recognize the risk of diabetes associated with statin therapy in a population at high risk for diabetes 2) Compare and contrast statin benefit to risk when treating patients in a
More informationThe Effect of Exercise Training on Cardiovascular Mortality Risk. Tori Haynes. April, 2015
The Effect of Exercise Training on Cardiovascular Mortality Risk by Tori Haynes April, 2015 Director of Thesis: Dr. Damon L. Swift, PhD. Major Department: Kinesiology PURPOSE: Clinicians use risk calculators
More informationCoronary Artery Calcium: Absence Makes the Heart Younger?
Coronary Artery Calcium: Absence Makes the Heart Younger? Parag H. Joshi, MD, MHS, FACC Assistant Professor of Medicine Division of Cardiology University of Texas Southwestern Medical Center Department
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationHDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
original article HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events Anand Rohatgi, M.D., Amit Khera, M.D., Jarett D. Berry, M.D., Edward G. Givens, B.A., Colby R. Ayers, M.S., Kyle E. Wedin,
More informationEpidemiology and Prevention. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Epidemiology and Prevention Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease Ann Marie Navar-Boggan, MD, PhD; Eric D. Peterson, MD, MPH; Ralph B. D Agostino, Sr, PhD;
More information